Akums Drugs and Pharmaceuticals enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025
10,235——
386386101
17.817.816.6
73.073.013.7
9,940——
−313−313−87.5
₹649.21——
3,4043,4043,077
2.1%2.1%0.4%
0.01×——
2.21×——
17.51×——
24.30×——
10.46×——
Reference items — trailing FY values
4,5024,3594,118
568522464
409367311
—1,181465
951951193
—948193
—231272
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AKUMS₹668.50

Akums Drugs and Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersALIVUSAGARWALEYEADVENZYMESAPLLTDAARTIPHARMAARTIDRUGSCORONAHCGMcap ₹10,235 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization——10,235.1
- Cash, Equiv & ST Investments101.2386.0386.0
+ Minority Interest16.617.817.8
+ Total Debt13.773.073.0
Enterprise Value——9,939.8
Net Debt (memo)-87.5-313.1-313.1
EV per Share——649.21
Total Capital3,077.33,404.13,404.1
Total Debt/Total Capital0.442.142.14
Total Debt/EV——0.01
EV/Sales——2.21
EV/EBITDA——17.51
EV/EBIT——24.30
EV/Free Cash Flow——10.46
Reference Items — Trailing FY Values
Sales4,118.24,359.04,501.6
EBITDA464.5522.0567.7
EBIT311.0367.5409.0
Operating Cash Flow465.21,181.2—
Free Cash Flow192.9950.7950.7
FCFF (free cash flow to the firm)192.8947.7—
Capital Expenditure272.3230.5—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.